Cybin Inc. (CYBN) Offfers Preclinical Data for CYB003 - Roth Capital

November 16, 2021 6:15 AM EST Send to a Friend
Roth Capital analyst Elemer Piros reiterated a Buy rating and $10.00 price target on Cybin Inc. (NYSE: CYBN) after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login